Doctor Rene Rettl
Medical University of Vienna, Vienna (Austria)
Member of:
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
DPD quantification correlates with ECV and disease severity in patients with ATTR-CM
Event: ESC Congress 2024
Topic: Infiltrative Myocardial Disease
Session: Cardiac amyloidosis: how to stage and score
DPD quantification correlates with ECV and disease severity in transthyretin cardiac amyloidosis
Event: Heart Failure 2024
Topic: Hypertrophic Cardiomyopathy
Session: Cardiomyopathies: present and future
Novel SPECT/CT biomarker in transthyretin cardiac amyloidosis: correlation with myocardial amyloid load and cardiac structure and function
Event: ESC Congress 2023
Topic: Imaging of Myocardial Disease
Session: New imaging insights into cardiomyopathies
Monitoring patisiran and inotersen treatment with quantitative SPECT/CT in hereditary transthyretin amyloid cardiomyopathy
Event: ESC Congress 2023
Topic: Infiltrative Myocardial Disease
Session: Cardiac amyloidosis: prognosis and treatment monitoring
Two-dimensional speckle-tracking echocardiography in tafamidis-treated patients with transthyretin amyloid cardiomyopathy: a glimmer of hope for viable therapy monitoring?
Event: ESC Congress 2022
Topic: Infiltrative Myocardial Disease
Session: Cardiac amyloidosis
Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy
Event: ESC Congress 2021 - The Digital Experience
Topic: Infiltrative Myocardial Disease
Session: Myocardial and pericardial disease e-posters
Quantification of myocardial amyloid deposition in tafamidis-treated patients with transthyretin amyloid cardiomyopathy
Event: ESC Congress 2021 - The Digital Experience
Topic: Infiltrative Myocardial Disease
Session: Myocardial and pericardial disease e-posters
Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
Event: Heart Failure 2021
Topic: Hypertrophic Cardiomyopathy
Session: Myocardial Disease
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
Event: Heart Failure 2021
Topic: Hypertrophic Cardiomyopathy
Session: Young Investigator Award: clinical research
Effects of tafamidis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy
Event: ESC Congress 2020
Topic: Treatment
Session: Chronic Heart Failure ePosters
